RE: The Efficacy and Safety of SGLT2 Inhibitor in Kidney Transplant Recipients With Diabetes

Affiliations

Comment

Jeong-Hoon Lim et al. Transplantation. 2023.

. 2023 Mar 1;107(3):e80-e81.

doi: 10.1097/TP.0000000000004471. Epub 2023 Feb 21.

¹ Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

No abstract available

Comment on

The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients.
Lim JH, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS, Lee H, Kim YL, Kim CD, Park SH, Lee JS, Yoo KD, Son HE, Jeong JC, Lee J, Lee JP, Cho JH. Lim JH, et al. Transplantation. 2022 Sep 1;106(9):e404-e412. doi: 10.1097/TP.0000000000004228. Epub 2022 Jun 30. Transplantation. 2022. PMID: 35768908
RE: Time-dependent Bias Existing in Their Statistical Analysis Must Be Properly Controlled/Avoided Before Drawing Any Conclusions.
Gaynor JJ, Tabbara MM, Ciancio G. Gaynor JJ, et al. Transplantation. 2023 Mar 1;107(3):e78-e79. doi: 10.1097/TP.0000000000004470. Epub 2023 Feb 21. Transplantation. 2023. PMID: 36808848 No abstract available.

1. Gaynor JJ, Tabbara MM, Ciancio G. Time-dependent bias existing in their statistical analysis must be properly controlled/avoided prior to drawing any conclusions. Transplantation. 2023;107:e78–e79.
1. Lim JH, Kwon S, Jeon Y, et al. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation. 2022;106:e404–e412.
1. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
1. Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
1. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.